Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can less be more? trial tests cutting RA medication doses

NCT ID NCT06687551

Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial asks whether people with rheumatoid arthritis who have low disease activity can safely reduce their JAK inhibitor dose without losing control of their symptoms. Participants will either follow a step-by-step dose-tapering plan or continue their usual full-dose medication. Researchers will track how many patients maintain low disease activity after a year, as well as any flare-ups, to see if a lower dose can work just as well.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JAK inhibitors (baricitinib, filgotinib, or tofacitinib) at reduced doses
What this could lead to
If successful, this could show that many RA patients can safely lower their medication dose while keeping the disease in check, potentially reducing side effects and costs.
What could go wrong
The trial is testing a strategy, not a new drug, and results may vary. Tapering could lead to disease flares in some patients, and the findings may not apply to all JAK inhibitors or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 308 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

The inclusion criteria will be 1. Aged ≥ 18 years at baseline. 2. Rheumatoid arthritis defined by the ACR/EULAR criteria. 3. Treated with a JAK inhibitor, full dose for at least 6 months. 4. The JAK inhibitor is prescribed as monotherapy or combined with a csDMARD with a stable dosage for at least 3 months before inclusion. 5. Being in LDA (CDAI≤10) for at least 6 months. 6. With a CRP level below the laboratory standard within the month before the inclusion visit. 7. Women of childbearing potential (WCBP) must have a negative pregnancy test before starting study The non-inclusion criteria will be: 1. Concomitant disease needing to be treated by the JAK inhibitor at full-dose (for example inflammatory bowel disease). 2. Patient with a history of JAK-inhibitor dose reduction/spacing before enrollment in the study with the JAK-inhibitor currently being taken. 3. Evidence of flare-up within the last 6 months prior to the inclusion. 4. Patient who received glucocorticoids \> 5mg/day in the 3 months prior the inclusion because of the disease activity of the RA. 5. Patient requiring corticoid joint injections in the 3 months prior to inclusion or with scheduled joint injections, to control disease activity. 6. Patient at risk for complication according to the ANSM (60) (current or past smokers, patients at risk of VTE, cancer or major cardiovascular problems, aged ≥ 65 years) at baseline AND currently taking baricitinib or filgotinib. 7. Patient taking associated bDMARD (including anti-TNF, anti-IL6, anti-CD20, abatacept, anti-IL17, anti-IL12/23, anti-IL23, anti-IL1, anti-BAFF, anti-IL5 pathways). 8. Patient taking immunotherapy for neoplasia. 9. Surgery scheduled in the next 12 months. 10. Fibromyalgia according to the physician's opinion. 11. Anticipated poor compliance with the strategy. 12. Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation. 13. Alcohol and/or drug misuse as determined by the investigator. 14. Pregnancy or breastfeeding. 15. Non-affiliation to the French Social Security System. 16. Patient unwilling to sign the informed consent form. 17. Patient under legal protection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis (RA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis (RA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU de Nancy

    RECRUITING

    Nancy, France

  • CHU Dupuytren 2

    RECRUITING

    Limoges, France

  • CHU Le Mans

    RECRUITING

    Le Mans, France

  • CHU d'Amiens

    RECRUITING

    Amiens, France

  • CHU de Clermont-Ferrand

    RECRUITING

    Clermont-Ferrand, France

  • CHU de Rouen

    RECRUITING

    Rouen, France

  • CHU de Tours

    RECRUITING

    Tours, France

  • GH Paris Saint-Joseph

    RECRUITING

    Paris, France

  • Groupe hospitalier Pitié-Salpêtrière

    RECRUITING

    Paris, France

  • Hopital Cochin

    RECRUITING

    Paris, France

  • Hopital Lariboisière

    RECRUITING

    Paris, France

  • Hopital Maison Blanche

    RECRUITING

    Reims, France

  • Hopital Nord

    RECRUITING

    Saint-Etienne, France

  • Hopital Saint Antoine

    RECRUITING

    Paris, France

  • Hôpital Bicêtre

    RECRUITING

    Paris, France

  • Hôpital Hautepierre

    RECRUITING

    Strasbourg, France

  • Hôpital LAPEYRONIE

    RECRUITING

    Montpellier, France

  • Hôpital Pasteur 2

    RECRUITING

    Nice, France

  • Hôpital Pellegrin

    RECRUITING

    Bordeaux, France

  • Hôpital Saint Philibert

    RECRUITING

    Lille, France

  • Hôpital Sainte Marguerite

    RECRUITING

    Marseille, France

  • La Cavale Blanche

    RECRUITING

    Brest, France

  • Nouvel Hôpital Orléans La Source

    RECRUITING

    Orléans, France

  • UH Toulouse

    RECRUITING

    Toulouse, Occitanie, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.